GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pezulepistat   Click here for help

GtoPdb Ligand ID: 14103

Synonyms: GDC-5780 | RG6319
Compound class: Synthetic organic
Comment: Pezulepistat (formerly RG6319 and GDC-5780) is the INN for an inhibitor of bacterial LepB with activity against Gram-negative bacteria (included in WHO INN proposed list 133, 10th July 2025). The chemical structure is claimed in patent WO2020243155A1 (Genentech and Hoffmann-La Roche) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 24
Hydrogen bond donors 12
Rotatable bonds 20
Topological polar surface area 407.41
Molecular weight 1008.11
XLogP -5.81
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=NC(=NC(=C1C(=O)N[C@@H](CNS(=O)(=O)N)C(=O)N(C)[C@H]2C3=CC(=C(C(=C3)OC[C@@H](CN)O)O)C4=CC(=CC=C4OC[C@@H](CN)O)C[C@@H](C(=O)O)NC(=O)[C@H](C)NC2=O)N)C5=CC=C(C=C5)C(C)(C)C
Isomeric SMILES OC1=C2C3=C(OC[C@@H](CN)O)C=CC(=C3)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N(C([C@@H](NC(=O)C=4C(C)=NC(=NC4N)C5=CC=C(C(C)(C)C)C=C5)CNS(N)(=O)=O)=O)C)C(=C2)C=C1OC[C@@H](CN)O
InChI InChI=1S/C46H61N11O13S/c1-22-36(39(49)56-40(52-22)25-8-10-27(11-9-25)46(3,4)5)42(62)55-33(19-51-71(50,67)68)44(64)57(6)37-26-15-31(38(60)35(16-26)70-21-29(59)18-48)30-13-24(7-12-34(30)69-20-28(58)17-47)14-32(45(65)66)54-41(61)23(2)53-43(37)63/h7-13,15-16,23,28-29,32-33,37,51,58-60H,14,17-21,47-48H2,1-6H3,(H,53,63)(H,54,61)(H,55,62)(H,65,66)(H2,49,52,56)(H2,50,67,68)/t23-,28+,29+,32-,33-,37-/m0/s1
InChI Key MWMUFQHFVZYJCC-CPJAVKDOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Pezulepistat is being developed to treat complicated urinary tract infections (cUTIs) [1]. A first-in-human study (ISRCTN16073754), to evaluate the safety and pharmacokinetics of pezulepistat in healthy subjects, was registered in 2022.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Pezulepistat is an inhibitor of LepB, a bacterial type I signal peptidase. LepB is an essential inner membrane enzyme and an integral part of the protein export pathway [3].